Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announces that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%.
Read the full article: Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. //
Source: https://www.globenewswire.com/news-release/2024/12/27/3002352/0/en/Vincerx-Pharma-Enters-into-a-Binding-Term-Sheet-for-a-Strategic-Merger-with-Oqory-Inc.html